Yu Ou

1.4k total citations
48 papers, 1.1k citations indexed

About

Yu Ou is a scholar working on Molecular Biology, Epidemiology and Surgery. According to data from OpenAlex, Yu Ou has authored 48 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 10 papers in Epidemiology and 6 papers in Surgery. Recurrent topics in Yu Ou's work include Natural product bioactivities and synthesis (5 papers), Liver Disease Diagnosis and Treatment (5 papers) and Diet, Metabolism, and Disease (5 papers). Yu Ou is often cited by papers focused on Natural product bioactivities and synthesis (5 papers), Liver Disease Diagnosis and Treatment (5 papers) and Diet, Metabolism, and Disease (5 papers). Yu Ou collaborates with scholars based in China, United States and United Kingdom. Yu Ou's co-authors include Xuegan Yang, Gaoyong Liao, Xiaodong Cheng, Xiaodong Cheng, Qin Pan, WU Wu-tong, Bing Gao, Dan Siskind, Steve Kisely and Lin Lin and has published in prestigious journals such as PLoS ONE, Cancer Research and Journal of Agricultural and Food Chemistry.

In The Last Decade

Yu Ou

47 papers receiving 1.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Yu Ou 490 181 120 117 96 48 1.1k
C. Anthony Rupar 809 1.7× 56 0.3× 47 0.4× 74 0.6× 125 1.3× 80 1.6k
Maria Lönn 1.2k 2.5× 88 0.5× 36 0.3× 23 0.2× 66 0.7× 26 1.7k
Shusuke Hashimoto 657 1.3× 67 0.4× 32 0.3× 80 0.7× 41 0.4× 46 1.7k
Nuris Ledón 464 0.9× 506 2.8× 11 0.1× 36 0.3× 35 0.4× 32 1.5k
Ana Marı́a Puebla-Pérez 373 0.8× 69 0.4× 12 0.1× 79 0.7× 24 0.3× 71 974
Bianka Bojková 389 0.8× 17 0.1× 36 0.3× 80 0.7× 36 0.4× 56 956
Wenwen Zhang 322 0.7× 51 0.3× 7 0.1× 76 0.6× 196 2.0× 40 932
Suraneni V.K. Mahipal 280 0.6× 191 1.1× 11 0.1× 24 0.2× 15 0.2× 8 687
Soo-Jung Park 704 1.4× 15 0.1× 30 0.3× 48 0.4× 106 1.1× 96 1.4k
Kartar Singh 618 1.3× 21 0.1× 20 0.2× 55 0.5× 65 0.7× 58 1.3k

Countries citing papers authored by Yu Ou

Since Specialization
Citations

This map shows the geographic impact of Yu Ou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Ou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Ou more than expected).

Fields of papers citing papers by Yu Ou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Ou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Ou. The network helps show where Yu Ou may publish in the future.

Co-authorship network of co-authors of Yu Ou

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Ou. A scholar is included among the top collaborators of Yu Ou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Ou. Yu Ou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Peng, et al.. (2025). DRD2‐ Mediated AMPK Ubiquitination Regulates the Occurrence of Hepatic Steatosis. Liver International. 45(4). e70053–e70053.
2.
Lu, Yunbiao, et al.. (2023). A bovine milk-derived peptide ameliorates pancreatic β-cell dedifferentiation through PI3K/Akt/FOXO1 signaling in type 2 diabetes. Food & Function. 14(17). 8018–8029. 7 indexed citations
3.
Ma, Peng & Yu Ou. (2023). Correlation between the dopaminergic system and inflammation disease: a review. Molecular Biology Reports. 50(8). 7043–7053. 3 indexed citations
4.
Siskind, Dan, Surabhi Sinha, Yu Ou, et al.. (2021). Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. The British Journal of Psychiatry. 220(3). 115–120. 135 indexed citations
5.
Li, Qihao, et al.. (2021). A phycocyanin derived eicosapeptide attenuates lung fibrosis development. European Journal of Pharmacology. 908. 174356–174356. 8 indexed citations
6.
Yu, Xiaoping, Jianmin Liu, Xin Wang, et al.. (2020). The therapeutic potential of attenuated diphtheria toxin delivered by an adenovirus vector with survivin promoter on human lung cancer cells. Cancer Biology & Therapy. 22(1). 79–87. 4 indexed citations
7.
Zhang, Yu, Min Liu, Bingyu Chen, et al.. (2019). Aplnra/b Sequentially Regulate Organ Left-Right Patterning via Distinct Mechanisms. International Journal of Biological Sciences. 15(6). 1225–1239. 5 indexed citations
8.
Jia, Tao, Min Zhang, Lei Zhang, et al.. (2018). Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo. Biomedicine & Pharmacotherapy. 106. 1727–1733. 33 indexed citations
9.
Chen, Jingyao, Yanfeng Zhu, Weiwei Zhang, et al.. (2018). Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells. BMC Cancer. 18(1). 342–342. 64 indexed citations
10.
Ou, Yu, et al.. (2017). Synthesis and evaluation of an injectable everolimus prodrug. Bioorganic & Medicinal Chemistry Letters. 27(5). 1175–1178. 5 indexed citations
11.
Liao, Gaoyong, et al.. (2016). Phycocyanin Inhibits Tumorigenic Potential of Pancreatic Cancer Cells: Role of Apoptosis and Autophagy. Scientific Reports. 6(1). 34564–34564. 101 indexed citations
12.
Zhu, Lei, et al.. (2016). EPSAH, an exopolysaccharide from Aphanothece halophytica GR02, improves both cellular and humoral immunity as a novel polysaccharide adjuvant. Chinese Journal of Natural Medicines. 14(7). 541–548. 7 indexed citations
13.
Ou, Yu, et al.. (2016). Phycocyanin ameliorates alloxan-induced diabetes mellitus in mice: Involved in insulin signaling pathway and GK expression. Chemico-Biological Interactions. 247. 49–54. 37 indexed citations
14.
Wang, Xuequan, Meiling Lü, Yang Shi, Yu Ou, & Xiaodong Cheng. (2015). Discovery of Novel New Delhi Metallo-β-Lactamases-1 Inhibitors by Multistep Virtual Screening. PLoS ONE. 10(3). e0118290–e0118290. 24 indexed citations
15.
Mei, Fang, et al.. (2013). Lithium Inhibits Tumorigenic Potential of PDA Cells through Targeting Hedgehog-GLI Signaling Pathway. PLoS ONE. 8(4). e61457–e61457. 37 indexed citations
16.
Ou, Yu, Lin Lin, Xuegan Yang, Qin Pan, & Xiaodong Cheng. (2013). Antidiabetic potential of phycocyanin: Effects on KKAy mice. Pharmaceutical Biology. 51(5). 539–544. 68 indexed citations
17.
Ou, Yu, Gaoyong Liao, Zhijun Yuan, & WU Wu-tong. (2012). Protective Effect of Recombinant Hirudin Variant III against Galactose-Mediated Rat Lens Epithelial Cell Damage. Current Eye Research. 37(3). 187–194. 9 indexed citations
19.
Ou, Yu, Shan Zheng, Lin Lin, Qizhou Jiang, & Xuegan Yang. (2010). Protective effect of C-phycocyanin against carbon tetrachloride-induced hepatocyte damage in vitro and in vivo. Chemico-Biological Interactions. 185(2). 94–100. 76 indexed citations
20.
Ou, Yu, et al.. (2008). Intracellular GSH and ROS levels may be related to galactose-mediated human lens epithelial cell apoptosis: Role of recombinant hirudin variant III. Chemico-Biological Interactions. 179(2-3). 103–109. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026